iShares Biotechnology ETF
829 hedge funds and large institutions have $3.98B invested in iShares Biotechnology ETF in 2025 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 193 increasing their positions, 359 reducing their positions, and 80 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less funds holding in top 10
Funds holding in top 10: →
38% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 80
46% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 359
54% less call options, than puts
Call options by funds: $293M | Put options by funds: $630M
Holders
829
Holding in Top 10
8
Calls
$293M
Puts
$630M
Top Buyers
| 1 | +$183M | |
| 2 | +$42.5M | |
| 3 | +$27.7M | |
| 4 |
JP Morgan Chase
New York
|
+$22.2M |
| 5 |
Squarepoint
New York
|
+$9.04M |
Top Sellers
| 1 | -$230M | |
| 2 | -$91.4M | |
| 3 | -$70.8M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$61M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$59.9M |